What is Craif?
Craif is a pioneering medical technology firm dedicated to the early detection and optimization of disease treatment through advanced exosome analysis. By utilizing urine as a primary diagnostic medium, the company has developed a proprietary platform that identifies biomarkers associated with various pathologies long before traditional symptoms manifest. This approach not only enhances patient comfort but also significantly improves clinical outcomes by enabling early intervention. As the company scales, it remains focused on integrating its diagnostic solutions into standard healthcare workflows, aiming to foster a society where proactive health management is accessible and routine.
How much funding has Craif raised?
Craif has raised a total of $28.3M across 2 funding rounds:
Series C
$6.3M
Series C
$22M
Series C (2024): $6.3M, investors not publicly disclosed
Series C (2025): $22M led by Aozora Bank and Unreasonable Group
Key Investors in Craif
Aozora Bank
Aozora Bank is a prominent Japanese financial institution providing a comprehensive suite of banking products and services, including specialized corporate financing and international capital management.
Unreasonable Group
Unreasonable Group is a global organization that supports entrepreneurs solving society's toughest challenges through accelerator programs, private equity, and an extensive network of mentors.
Undisclosed Investor
Undisclosed investor participating in the funding round.
What's next for Craif?
With this latest capital injection, Craif is poised to accelerate its clinical research and expand its operational footprint. The strategic focus will likely shift toward obtaining regulatory approvals in key international markets and enhancing the scalability of its exosome collection infrastructure. By strengthening its partnerships with global financial and impact-oriented institutions, Craif is well-positioned to transition from a research-heavy startup to a commercial-stage enterprise. The company's roadmap includes deepening its data analytics capabilities to refine diagnostic accuracy, ultimately aiming to set a new global standard for non-invasive, early-stage disease screening and personalized treatment optimization.
See full Craif company page
